Payment overview · 2025
General Payments
$713.11
30 reported records · 12 companies
Healthcare provider profile · identity verified
Juan P Suarez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1992794556
Verified facts
What the public records show
CMS Open Payments records show Juan P Suarez, MD received $713.11 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.31 | 16.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.76 | 13.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $88.06 | 12.3% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $83.20 | 11.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.53 | 9.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.34 | 9.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.74 | 6.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.07 | 5.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.89 | 5.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.46 | 3.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.00 | 3.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.75 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $713.11 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.31 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.31 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.06 | 4 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $83.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.53 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.34 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.34 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $67.98 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.78 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.98 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.07 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 18 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 90 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 65 |
| Metformin Hcl | Metformin Hcl | 180 | 52 |
| Losartan Potassium | Losartan Potassium | 162 | 56 |
| Cefdinir | Cefdinir | 145 | 108 |
| Lisinopril | Lisinopril | 139 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 44 |
| Montelukast Sodium | Montelukast Sodium | 126 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 44 |
| Alprazolam | Alprazolam | 108 | 28 |
| Omeprazole | Omeprazole | 105 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 41 |
| Atenolol | Atenolol | 91 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 27 |
| Ozempic | Semaglutide | 89 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 26 |
| Eliquis | Apixaban | 80 | 22 |
| Gabapentin | Gabapentin | 79 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 26 |
| Carvedilol | Carvedilol | 78 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 25 |
| Alendronate Sodium | Alendronate Sodium | 71 | 27 |
| Farxiga | Dapagliflozin Propanediol | 69 | 17 |
| Furosemide | Furosemide | 69 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 16 |
| Pregabalin | Pregabalin | 63 | 15 |
| Simvastatin | Simvastatin | 63 | 19 |
| Temazepam | Temazepam | 63 | suppressed |
| Meloxicam | Meloxicam | 60 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 13 |
| Methylprednisolone | Methylprednisolone | 56 | 45 |
| Trazodone Hcl | Trazodone Hcl | 54 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 12 |
| Clonazepam | Clonazepam | 51 | 13 |
| Synthroid | Levothyroxine Sodium | 51 | 18 |
| Tramadol Hcl | Tramadol Hcl | 51 | 18 |
| Azelastine Hcl | Azelastine Hcl | 50 | 21 |
| Donepezil Hcl | Donepezil Hcl | 50 | 17 |
| Sertraline Hcl | Sertraline Hcl | 50 | 11 |
| Allopurinol | Allopurinol | 48 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 40 |
| Jardiance | Empagliflozin | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 13 |
| Mupirocin | Mupirocin | 39 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 16 |
| Ezetimibe | Ezetimibe | 38 | 12 |
| Azithromycin | Azithromycin | 37 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Valacyclovir | Valacyclovir Hcl | 26 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Tadalafil | Tadalafil | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Linezolid | Linezolid | 21 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Unithroid | Levothyroxine Sodium | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 13 |
| Testosterone | Testosterone | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $713.11 · 30 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, Cologuard Collection Kit, EDARBI, ELIQUIS, EVENITY, FARXIGA, Korlym, MAKO, NURTEC ODT, Ozempic, QULIPTA, Repatha, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error